APGE

Equibles Rating blended score · not investment advice

Overall

Buy

Technical · trend & momentum Buy

◦ 50 / 200-day cross no cross

+ Price vs 200-day avg +80% above

+ Price vs 50-day avg +44% above

− RSI (14) 81 · overbought

+ MACD trend positive

+ 52-week position 99% · near high

Sentiment · smart money Bullish

◦ Trend (MA cross) 50d $93 › 200d $74 — 50d above 200d

+ Institutional flow 1 of 229 funds reported for Jun 30 · net +11 sh shares

− Insider flow Net -$6.2M over 90 days · 100% sells

+ Short interest 13.99% of float · ▼ -0.5% MoM · 10.3 days cover

◦ Volume signal Volume near normal

+ Institution breadth 229 holders — near 3-yr high, broad support

Fundamentals Weak

− EPS growth −28% Y/Y

− Free cash flow $-232.6M

+ Balance sheet net cash $131.5M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next

Next earnings call

Aug 10, 2026 Est · unconfirmed · in 5 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 11, 2026

Technicals

trend & momentum for long-term holders Buy

1 · 1 · 4

50 / 200-day cross

no cross Neutral

Price vs 200-day avg

+80% above Bullish

Price vs 50-day avg

+44% above Bullish

RSI (14)

81 · overbought Bearish

MACD trend

positive Bullish

52-week position

99% · near high Bullish

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $93 › 200d $74 — 50d above 200d

Institutional flow Accumulating

1 of 229 funds reported for Jun 30 · net +11 sh shares

Insider flow Distributing

Net -$6.2M over 90 days · 100% sells

Short interest Falling

13.99% of float · ▼ -0.5% MoM · 10.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

229 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $34 Now $133 · 99% 52-wk high $134

vs 200-day avg +80% vs 50-day avg +44%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
APGE Apogee Therapeutics, Inc. this stock	$12.13B	+76.1%	—	—	14.0%
AKTX Akari Therapeutics Plc	$953.21B	-9.9%	—	—	0.0%
ONC BeOne Medicines Ltd.	$470.30B	-2.0%	+22179.2%	957.1	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$134.02B	+16.5%	+46.2%	31.3	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$69.80B	-15.1%	+20.8%	16.3	3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

229

% held: 106.7%
Reported: 1 of 229
Top holder: T. Rowe Price Investment…

Held Float

View

Held by Funds

Fund positions

296

View

Short & Settlement

Short Interest Falling

Shares short

10.5M

Days to cover: 10.3d
Change: -48.9K sh

View

Short Volume

Short vol %

12%

As of: Jul 2, 2026

Short Total

View

Fails to Deliver

FTD shares

26.3K

Value: $2.3M
As of: Jun 8, 2026

View

Off-Exchange

Off-exchange %

53.5%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$6.2M

Buyers / Sellers: 0 / 3

Buyers Sellers

View

Financials

Net income (FY)

$-255.8M

EPS diluted: $-4.22

View

Filings

SEC Filings

Latest

8-K

Filed: Jun 22, 2026
This year: 14

View

Proposed Sales

Value

$2.2M

Shares: 16.5K
Filed: Jul 1, 2026

View

Earnings & Events

Earnings Calls

Last call

Jun 3, 2026

View

Performance

	5D	20D	120D	MTD	YTD
APGE	+0.2%	+57.9%	+71.5%	+0.1%	+76.1%
SPY	+1.4%	-1.3%	+8.0%	-0.3%	+9.2%
vs SPY	-1.3%	+59.1%	+63.5%	+0.4%	+66.9%

Price & Indicators

Technicals

Versus peers

At a glance

Performance